In a decisive turn of events, the Centers for Medicare & Medicaid Services (CMS) announced an indefinite postponement of the Medicare Part D portion of the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) model on April 21, 2026. The decision marks a significant setback for the Biden-Harris administration’s efforts to standardize and broaden access to GLP-1 medications—drugs that have reshaped the treatment landscape for obesity and metabolic health. While the initiative was designed to circumvent historical statutory limitations on weight-loss drugs in federal programs, the breakdown highlights the massive leverage held by Pharmacy Benefit Managers (PBMs) and major insurance carriers like CVS and UnitedHealth Group, whose reluctance to participate ultimately rendered the model untenable in its current form.
The Collapse of the BALANCE Model for Medicare Part D
Inside the Delay: Why Insurers Balked
The core issue precipitating the collapse of the BALANCE model lies in the clash between federal administrative goals and private sector operational realities. The BALANCE model was envisioned as a voluntary, yet highly structured, pathway where CMS would negotiate directly with manufacturers—specifically Novo Nordisk and Eli Lilly—to set guaranteed net prices and standardized coverage terms. This effectively aimed to bypass the traditional, often opaque, rebate-driven negotiations that define the current PBM landscape.
However, major industry players found the proposed structure problematic. During recent earnings calls and industry dialogues, executives from insurance giants, including UnitedHealth Group, raised pointed questions about the operational feasibility of the model. Reports indicate that the primary contention was the risk-sharing profile and the administrative burden of implementing lifestyle intervention requirements. For PBMs and plans that rely on existing formulary management strategies, the BALANCE model’s requirement to accept CMS-negotiated terms appeared to undercut their ability to manage drug spend on their own terms. When CVS, one of the nation’s largest pharmacy benefit managers, signaled its decision to decline participation, the feasibility of a critical-mass enrollment strategy became mathematically impossible. Without the buy-in of the major plan sponsors, the program lost its utility, forcing CMS to pull the plug before a disastrous rollout.
The “Bridge” Extension: What Beneficiaries Need to Know
For the millions of Americans covered by Medicare Part D who are currently seeking treatment for obesity, the collapse of the BALANCE model creates immediate uncertainty. However, CMS has attempted to soften the blow by extending the “Medicare GLP-1 Bridge” program through December 31, 2027. This temporary payment demonstration, originally designed as a short-term stopgap until the BALANCE model could take full effect in 2027, now becomes the primary mechanism for access.
The Bridge program operates outside the traditional Part D benefit structure, effectively removing the PBMs from the financial risk calculation. By directly managing these payments, CMS can ensure that eligible beneficiaries still receive access to certain GLP-1s, albeit under restricted criteria. The extension is a vital lifeline, but it is not a permanent solution. Beneficiaries should anticipate that access will remain limited to those meeting specific, rigid criteria, and the paperwork burden for navigating these temporary pathways will persist throughout 2026 and 2027. Patients are advised to consult their plan providers immediately, as the extension of the Bridge program changes the long-term outlook for formulary updates.
Medicaid Remains the Exception
Crucially, the indefinite delay announced by CMS applies specifically to the Medicare Part D portion of the BALANCE model. The initiative continues to move forward for state Medicaid agencies. As of the latest update, states are still encouraged to submit applications for participation through July 31, 2026. This distinction reflects the different regulatory environments of the two programs. Medicaid programs have historically held more flexibility regarding optional benefit coverage, including weight-loss drugs, though actual implementation remains uneven across the country.
By keeping the Medicaid pathway open, CMS is attempting to preserve at least a portion of its original vision. States that choose to join the model can still leverage the negotiated prices achieved by CMS in its discussions with pharmaceutical manufacturers. This bifurcated outcome—a dead-end for Medicare but a continued path for Medicaid—suggests that the federal government is prioritizing state-level implementation where they can exercise more direct control, while conceding that the Medicare Part D ecosystem is currently too fragmented and resistant to centralized intervention.
Market Reactions: Lilly and Novo Nordisk on Notice
The pharmaceutical industry, particularly Eli Lilly and Novo Nordisk, felt the immediate sting of the announcement. Both companies, which had engaged in direct, high-level negotiations with CMS to solidify their participation in the BALANCE model, saw their stock prices dip on April 22, 2026. The market reaction reflects the loss of a massive, guaranteed pipeline for their blockbuster drugs, Zepbound and Ozempic/Wegovy.
Analysts have noted that while this delay is negative for short-term revenue projections, the long-term trend lines for GLP-1 utilization remain robust. Telehealth platforms and direct-to-consumer models like LillyDirect are likely to see an increase in activity as patients who are denied coverage under the now-stalled Medicare path seek alternative, out-of-pocket, or manufacturer-sponsored routes. The failure of the BALANCE model forces the pharmaceutical industry to reassess its strategy: relying on federal administrative models to force coverage adoption may be less effective than individual-level market capture through physician and direct-to-patient channels.
The Policy Failure and Future Implications
The collapse of the BALANCE model is a stark case study in the limits of administrative power within the U.S. healthcare system. Despite the backing of an administration focused on lowering drug costs and enhancing public health, the structural reality of the Medicare Part D program—dominated by a few powerful PBMs—proved too rigid to accommodate a top-down federal model. This failure will likely spark a heated debate in Washington regarding the need for statutory reform versus administrative demonstrations. Proponents of obesity care access argue that as long as Medicare remains prohibited by law from covering weight-loss medications, temporary models like BALANCE will always be fragile and susceptible to PBM pushback. The industry now enters a period of uncertainty, with neither a clear path toward comprehensive coverage nor a retreat from the growing public demand for these life-changing medications.
FAQ: People Also Ask
1. What happens to the BALANCE model now that it is delayed for Medicare?
The Medicare Part D portion of the BALANCE model is indefinitely postponed. CMS will rely on the Medicare GLP-1 Bridge program, extended through December 2027, to provide access in the interim.
2. Are GLP-1 drugs covered by Medicare right now?
Generally, no. Medicare is legally prohibited from covering drugs strictly for weight loss. The GLP-1 Bridge program and the now-postponed BALANCE model were specific attempts to create temporary exceptions to this rule.
3. Is the Medicaid portion of the BALANCE model still active?
Yes. CMS is continuing to accept applications from state Medicaid agencies for the BALANCE model through July 31, 2026. States can choose to opt-in based on their specific program needs.
4. Will Eli Lilly and Novo Nordisk still lower prices for GLP-1s?
The manufacturers had agreed to negotiated pricing as part of the BALANCE model. With the Medicare portion halted, it is unclear if those specific negotiated prices will be applied to all patients, though they may still be honored for states that choose to participate in the Medicaid portion of the model.
